| Literature DB >> 27181715 |
Martin Hoenigl1,2,3, Antoine Chaillon1, Sheldon R Morris1, Susan J Little1.
Abstract
Approximately 80% of new HIV infections in the United States occur in men. Four out of five men diagnosed with HIV infection are men who have sex with men (MSM), with an increasing proportion of young MSM (i.e. ≤24 years of age). We performed a retrospective analysis 11,873 cisgender men participating in a community based HIV screening program in San Diego between 2008 and 2014 to characterize the HIV prevalence and sexual risk behaviors among young men. In young heterosexual men HIV prevalence was lower compared to heterosexual men between 25 and 49 years of age (0.3% vs. 1.4%, p = 0.043). Among young MSM, HIV prevalence was 5.5%, per test positivity rate 3.6%, and HIV incidence 3.4 per 100 person years (95% CI 2.2-5.4). Per test positivity rate (p = 0.008) and incidence (p < 0.001) were significantly higher among young MSM than among MSM above 24-years of age. Young MSM diagnosed with HIV infection reported significantly more serodiscordant condomless anal intercourse, bacterial sexually transmitted infections, and higher rates of methamphetamine and gamma hydroxybutyrate use when compared to young MSM who tested negative. In conclusion, young MSM are particularly vulnerable to HIV infection and may represent ideal candidates for targeted prevention interventions that increase testing uptake and/or decrease the risk of acquiring HIV infection.Entities:
Mesh:
Year: 2016 PMID: 27181715 PMCID: PMC4867437 DOI: 10.1038/srep25927
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
HIV Prevalence and Incidence, per Test Positivity and Demographics of Study Participants.
| Men ≤ 24 years of age (n = 1639) | Men > 24 years and <50 years of age (n = 6146) | Men ≥ 50 years of age (n = 1141) | P value | Men ≤ 24 years of age (n = 577) | Men > 24 years and <50 years of age (n = 1907) | Men ≥ 50 years of age (n = 460) | P value | |
|---|---|---|---|---|---|---|---|---|
| HIV Prevalence | 90 (5.5%) | 300 (4.9%) | 29 (2.5%) | <0.001 | 2 (0.3%) | 26 (1.4%) | 3 (0.7%) | n.s. |
| Acute HIV | 20 (1.2%) | 67 (1.1%) | 6 (0.5%) | — | 0 | 0 | 0 | — |
| Early HIV | 23 (1.4%) | 78 (1.3%) | 6 (0.5%) | — | 0 | 2 (0.1%) | 0 | — |
| Chronic HIV | 47 (2.9%) | 155 (2.5%) | 17 (1.5%) | — | 2 (0.3%) | 24 (1.3%) | 3 (0.7%) | — |
| Repeat Testers | 409 (25.0%) | 2145 (34.9%) | 400 (35.1%) | <0.001 | 40 (6.9%) | 223 (11.7%) | 44 (9.6%) | 0.004 |
| Per Test Positivity Rate (number of tests) | 3.6% (2482) | 2.4% (12,495) | 1.2% (2346) | <0.001 | 0.3% (643) | 1.1% (2373) | 0.5% (547) | n.s. |
| HIV Incidence among repeat Testers per 100 person years (number of incident infections) | 3.40 (17) | 1.79 (81) | 0.85 (8) | <0.001 | 0.0 (0) | 0.26 (1) | 0.0 (0) | n.s. |
| Age (years; median, IQR) | 22 (21–23) | 33 (29–40) | 55 (52–62) | <0.001 | 22 (20–23) | 34 (29–41) | 55 (52–60) | <0.001 |
| Hispanic Ethnicity | 627/1596 (39.3%) | 1667/5991 (27.8%) | 121/1103 (11.0%) | <0.001 | 240/555 (43.2%) | 536/1834 (29.2%) | 80/443 (18.1%) | <0.001 |
| Race | — | — | — | <0.001 | — | — | — | <0.001 |
| White | 808/1490 (54.2%) | 3883/5793 (67.0%) | 979/1107 (88.4%) | — | 280/533 (52.5%) | 1044/1803 (57.9%) | 308/446 (69.1%) | — |
| Black | 102/1490 (6.8%) | 333/5793 (5.7%) | 27/1107 (2.4%) | — | 53/533 (9.9%) | 237/1803 (13.1%) | 75/446 (16.8%) | — |
| Asian | 165/1490 (11.1%) | 410/5793 (7.1%) | 19/1107 (1.7%) | — | 47/533 (8.8%) | 136/1803 (7.5%) | 9/446 (2.0%) | — |
| Pacific Islander | 35/1490 (2.3%) | 153/5793 (2.6%) | 7/1107 (0.6%) | — | 5/533 (0.9%) | 21/1803 (1.2%) | 1/446 (0.2%) | — |
| Native American | 18/1490 (1.2%) | 33/5793 (0.6%) | 1/1107 (0.1%) | — | 19/533 (3.6%) | 53/1803 (2.9%) | 4/446 (0.9%) | — |
| Other | 362/1490 (24.3%) | 981/5793 (16.9%) | 74/1107 (6.7%) | — | 129/533 (24.2%) | 312/1803 (17.3%) | 49/446 (11.0%) | — |
Abbreviations: IQR, inter-quartile range; n.s.; not significant.
$includes men who have sex with men and women
*calculated using Chi-squared test.
¥Includes all cisgender men not self identifying as MSM and not reporting sexual intercourse with a male partner during the recent 12 months.
Risk Behaviour Reported for the 12 months prior to diagnosis/last HIV test in MSM and heterosexual men ≤24 years and ≥50 years of age undergoing community based HIV testing.
| Men who have sex with men ≤24 years of age (n = 1639) | Men who have sex with men ≥50 years of age (n = 1141) | P value | Heterosexual Men ≤24 years of age (n = 577) | Heterosexual Men ≥50 years of age (n = 460) | P value | |
|---|---|---|---|---|---|---|
| Total Number of partners (median, IQR) | 6 (3–11) | 5 (3–12) | n.s. | 3 (1–5) | 2 (1–3) | <0.001 |
| Intercourse with Male partner | 1639/1639 (100%) | 1141/1141 (100%) | n.s. | 0/577 (0%) | 0/460 (0%) | n.s. |
| Number of Male partners (median, IQR) | 5 (3–10) | 5 (3–12) | n.s. | — | — | — |
| Intercourse with Female partner | 220/1639 (13.4%) | 110/1141 (9.6%) | 0.029 | 537/577 (93.1%) | 381/460 (82.8%) | <0.001 |
| Number of Female partners (median, IQR) | 2 (1–3) | 1 (1–2) | n.s. | 3 (1–5) | 2 (1–4) | <0.001 |
| Intercourse with Transgender partner | 15/1634 (0.9%) | 14/1141 (1.2%) | n.s. | 13/574 (2.3%) | 15/460 (3.3%) | n.s. |
| Number of Transgender partners (median, IQR) | 1 (1–2) | 1 (1–1) | n.s. | 1 (1–1) | 1 (1–1) | n.s. |
| Intercourse with MSM | 100% | 100% | n.s. | 0% | 0% | n.s. |
| 10 or more total partners | 522/1634 (31.9%) | 398/1139 (34.9%) | n.s. | 59/568 (10.4%) | 30/449 (6.7%) | 0.049 |
| CIAI total | 974/1629 (59.8%) | 599/1132 (52.9%) | <0.001 | 96/509 (18.9%) | 56/367 (15.3%) | n.s. |
| CIAI with Female/Transgender | 23/215 (10.7%) | 18/109 (16.5%) | n.s. | 96/509 (18.9%) | 56/367 (15.3%) | n.s. |
| CIAI with Male | 969/1629 (59.5%) | 588/1132 (51.9%) | <0.001 | 0 | 0 | n.s. |
| CRAI | 967/1629 (59.4%) | 430/1134 (37.9%) | <0.001 | 1/577 (0.2%) | 0 | n.s. |
| CRAI and 5 or more partners | 624/1629 (38.3%) | 276/1134 (24.3%) | <0.001 | 1/577 (0.2%) | 0 | n.s. |
| CPVI | 89/216 (41.2%) | 78/105 (74.3%) | <0.001 | 395/518 (76.3%) | 288/370 (77.8%) | n.s. |
| CRAI with HIV positive | 89/1515 (5.9%) | 42/1104 (3.8%) | 0.021 | 0 | 0 | n.s. |
| Bacterial STI§ | 254/1639 (15.5%) | 59/1141 (5.2%) | <0.001 | 19/577 (3.3%) | 6/460 (1.3%) | n.s. |
| Non injection stimulant Drug use (i.e. methamphetamine, cocaine, poppers, GHB, ketamine, XTC) | 454/1639 (27.7%) | 208/1141 (18.2%) | <0.001 | 161/577 (27.9%) | 66/460 (14.3%) | <0.001 |
| Methamphetamine | 97/1639 (5.9%) | 53/1141 (4.6%) | n.s. | 74/577 (12.8%) | 43/460 (9.3%) | n.s. |
| GHB | 67/1639 (4.1%) | 25/1141 (2.2%) | 0.008 | 4/577 (0.7%) | 1/460 (0.2%) | n.s. |
| XTC | 236/1639 (14.4%) | 24/1141 (2.1%) | <0.001 | 74/577 (12.8%) | 4/460 (0.9%) | <0.001 |
| Nitrites, inhaled | 216/1639 (13.2%) | 146/1141 (12.8%) | n.s. | 4/577 (0.7%) | 2/460 (0.2%) | n.s. |
| Cocaine | 192/1639 (11.7%) | 24/1141 (2.1%) | <0.001 | 97/577 (16.8%) | 29/460 (6.3%) | <0.001 |
| IDU | 16/1639 (1.0%) | 13/1141 (1.1%) | n.s. | 28/577 (4.9%) | 21/460 (4.6%) | n.s. |
Risk behaviour not stratified by age for the overall MSM cohort including MSM 25–49 years of age has been published previously19.
Abbreviations: CIAI, condomless insertive anal intercourse; CPVI, condomless penetrative vaginal intercourse; CRAI, condomless receptive anal intercourse; GHB, gamma hydroxybutyrate; IDU, injection drug use; IQR, inter-quartile range; MSM, men who have sex with men; n.s.; not significant; STI, sexual transmitted infection; XTC = ecstasy.
*Calculated using Chi-square or Mann Whitney U test.
#With Transgender partner.
§Syphilis, chlamydia and gonorrhea.
¥Includes all males not selfidentifying as MSM and not reporting sexual intercourse with a male partner during the recent 12 months.
Risk Behaviour in young MSM (≤24 years of age) newly diagnosed with HIV Infection as compared to those with negative HIV Test Results.
| Young MSM with HIV Infection (n = 90) | Young MSM with negative HIV Test Results (n = 1549) | P value | |
|---|---|---|---|
| 6 (3–16) | 5 (3–10) | 0.055 | |
| 10/90 (11.1%) | 210/1549 (13.6%) | n.s. | |
| 36/90 (40.0%) | 463/1549 (29.9%) | 0.056 | |
| 66/88 (75.0%) | 903/1541 (58.6%) | 0.003 | |
| 74/89 (83.1%) | 893/1540 (58.0%) | <0.001 | |
| 45/89 (50.6%) | 579/1540 (37.6%) | 0.020 | |
| 21/79 (26.6%) | 68/1436 (4.7%) | <0.001 | |
| 25/90 (27.8%) | 229/1549 (14.8%) | 0.002 | |
| 30/90 (33.3%) | 424/1549 (27.4%) | n.s. | |
| 16/90 (17.8%) | 81/1549 (5.2%) | <0.001 | |
| 12/90 (13.3%) | 55/1549 (3.6%) | <0.001 | |
| 15/90 (16.7%) | 221/1549 (14.3%) | n.s. | |
| 13/90 (14.4%) | 203/1549 (13.1%) | n.s. | |
| 15/90 (16.7%) | 177/1549 (11.4%) | n.s. | |
| 2/90 (2.2%) | 14/1549 (0.9%) | n.s. | |
| 3 (1–7) | 2 (0–5) | <0.001 | |
Abbreviations: CIAI, condomless insertive anal intercourse; CRAI, condomless receptive anal intercourse; GHB, gamma hydroxybutyrate; IDU, injection drug use; IQR, inter-quartile range; MSM, men who have sex with men; n.s., not significant; STI, sexual transmitted infection
*Calculated using Chi-square or Mann Whitney U test. P-value displayed if p<0.06.
§Syphilis, chlamydia and gonorrhea.
XTC, ecstasy.